At 36 weeks, mean percentage weight reductions were 3.2% to 16.9% with retatrutide, 2.0% with dulaglutide and 3.0% with placebo
Apovian CM, Aronne L, Rubino D, et al
Patients should always inform their surgical team and anaesthetist about GLP-1 use, including the specific medication, dose, and timing of the last administration, to ensure appropriate perioperative planning
Nice piece in Digital Health Insights by Carrie Pallardy looking at the murky world of direct-to-consumer #telemedicine and GLP-1s, especially companies providing compounded GLP-1s to patients who may not truly need them
Although our CCA showed generally low overlap across reviewsmitigating double-countingevidence aggregation was disproportionately driven by a small number of large, frequently cited cardiovascular outcome trials (CVOTs